Trial Profile
An Open- label, randomized, two-sequence, crossover Study of Upadacitinib in Healthy Male and Female Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Ketoconazole
- Indications Autoimmune disorders
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2017 New trial record